Physician profile
Dalton Ebel
NPI 1528611811
$2,154.11
in general payments reported to CMS, 2019-2025
29 companies · $228 in 2025
The $228 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $301 · 2021: $491 · 2022: $27.47 · 2023: $280 · 2024: $570 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,058 · Travel and Lodging: $20.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,058.06 |
| Travel and Lodging | $20.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $212.97 | 2023-2024 | |
| Amgen INC. | $210.07 | 2020-2024 | Tavneos |
| Abbvie INC. | $190.41 | 2019-2025 | |
| Novo Nordisk INC | $188.24 | 2019-2021 | |
| Lilly USA, LLC | $166.33 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $145.00 | 2021-2024 | Farxiga |
| Amarin Pharma, INC. | $131.45 | 2020-2021 | |
| Gilead Sciences, INC. | $107.79 | 2024 | Biktarvy |
| Alexion Pharmaceuticals, INC. | $94.57 | 2023 | |
| Abbott Laboratories | $90.30 | 2021 | |
| Mylan Specialty L.P. | $77.72 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $76.30 | 2023-2024 | Jynarque |
| Calliditas Therapeutics US INC. | $65.42 | 2024 | |
| Philips North America LLC | $57.86 | 2019 | |
| Vifor Pharma, INC. | $33.68 | 2023 | Veltassa, Korsuva |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $29.15 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.66 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.47 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $25.69 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.50 | 2021 | |
| Mozarc Medical US LLC | $22.94 | 2025 | Palindrome |
| Merck Sharp & Dohme LLC | $21.88 | 2023 | Prevymis |
| Vantive US Healthcare LLC | $20.99 | 2025 | Renal - Pd |
| Glaxosmithkline, LLC. | $20.59 | 2025 | Benlysta |
| Incyte Corporation | $20.17 | 2021 | |
| Ardelyx, INC. | $19.65 | 2023 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $16.63 | 2025 | Terlivaz |
| Janssen Pharmaceuticals, INC | $14.04 | 2021 | |
| Electromed, INC. | $13.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dalton Ebel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.